| Overview |
| bs-10271R-Cy3 |
| VAV3(Tyr141) Polyclonal Antibody, Cy3 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse, Rat |
| Human, Cow, Sheep, Horse |
| Specifications |
| Cy3 |
| Rabbit |
| KLH conjugated synthetic phosphopeptide derived from human VAV3 around the phosphorylation site of Tyr141 |
| Tyr141 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 10451 |
| Cytoplasm, Extracellular matrix |
| VAV3phospho Y141; Guanine nucleotide exchange factor VAV3; Protein vav 3; Protein vav3; VAV 3; Vav 3 guanine nucleotide exchange factor; VAV 3 oncogene; VAV 3 protein; VAV-3; Vav3; VAV3 oncogene; VAV3 protein; VAV3_HUMAN. |
| The Vav family of Rho guanine nucleotide exchange factors (GEFs) orchestrate signaling events following lymphocyte antigen receptor activation. Vav3, like Vav (also known as Vav1 or p95Vav), undergoes tyrosine phosphorylation downstream of T cell receptor cross-linkage, and subsequently interacts with 2 adaptor molecules, SLP76 and 3BP2. Following these events, however, the paths of Vav and Vav3 diverge; Vav affects IL-2 promotor activity, while Vav3 impacts gene transcription linked to serum response element (SRE). Furthermore, Vav3 expression follows a cell cycle-dependent pattern, with transient upregulation occuring during mitosis. Encforced Vav3 expression leads to the appearance of multinucleate cells, implicating a role for Vav3 in the control of cytokinesis. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz